Neovascular age-related macular degeneration: Decision making and optimal management

Eye

Volumn 24, Issue 3, 2010, Pages 497-505

  Harding, S P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Decision making; Management; Neovascular age related macular degeneration

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

CENTRAL SEROUS RETINOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED PRACTICE; FLUORESCENCE ANGIOGRAPHY; HEALTH CARE DELIVERY; HEALTH PRACTITIONER; HEALTH SERVICE; HUMAN; IMAGING SYSTEM; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PROLIFERATIVE RETINOPATHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; TISSUE INJURY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT PLANNING; VISION;

EID: 77949482261     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.316     Document Type: Conference Paper

References (30)

1. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin. One-year results of 2 randomized clinical trialsFTAP report 1. Arch Ophthalmol 1999; 117: 1329-1345.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizationFverteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
3. Scientific Department, Royal College of Ophthalmologists. Ranibizumab: the clinician's guide to commencing, continuing and discontinuing treatment. Royal College Ophthalmol 2008. http://www.rcophth.ac.uk/docs/ scientific/Ranibizumab---June-2008.pdf.
4. Scientific Department, Royal College of Ophthalmologists. Commissioning contemporary AMD Services: a guide for commissioners and clinicians. Version 3. Royal College Ophthalmol 2007. http://www.rcophth.ac.uk/docs/ publications/published-guidelines/ CommissionContempAMDServicesV3Final.pdf.
5. National Institute for Health and Clinical Excellence. Macular degeneration (age-related)Fpegaptanib and ranibizumab: final appraisal determination. 2009. http:// www.nice.org.uk/nicemedia/pdf/AMDFAD.pdf. Accessed 17 August 2009.
6. Scientific Department, Royal College of Ophthalmologists. Age-related macular degeneration. Guidelines for management. Royal College Ophthalmol 2009. http:// www.rcophth.ac.uk/docs/publications/ amd-guidelines-final-version-feb- 09.pdf.
7. American Academy of Ophthalmology. Summary benchmarks for preferred practice patterns guidelines. Am Acad Ophthalmol 2008, pp 6-7. http://one.aao.org/ asset.axd?ID=51fa23d9-f479-4884-abd6-67eb4534e446.
8. Scientific Department, Royal College of Ophthalmologists. Wet AMD rapid access referral form. Royal College Ophthalmol 2008. www.rcophth.ac.uk/docs/ publications/ Rapid-Access-Referral-Form-08.pdf. Accessed 31 October 2009.
9. Harding SP, Peto T, Muldrew KA, Patton WP, Chakravarthy U, Lenfestey PM, et al, VPDT Cohort Study Group. Is the presence of blood a reliable indicator of CNV subtype and activity? Report from the UK VPDT Cohort Reading Centre Network. Invest Ophthalmol Vis Sci 2007; 48; E-Abstract 5116.
10. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991; 109(9): 1242-1257.
11. Scott A, Bressler S. Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye 2009 [E-pub ahead of print 18 December 2009].
12. Lim T, Laude A, Tan C. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye 2009 (in press).
13. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2009; [Epub ahead of print 13 May 2009].
14. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al, the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
15. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular agerelated macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116(1): 57-65.
16. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, the ANCHOR Study Group. Improved vision-related function after ranibizumab vs photodynamic therapy. Arch Ophthalmol 2009; 127(1): 13-21.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al, the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
18. The intravitreal use of bevacizumab (avastin) in age related macular degeneration. http://www.rcophth.ac.uk/docs/ publications/published-guidelines/ avastin---the- intravitreal-use-of-bevacizumab---24th-february-2009.pdf. Accessed 17 August 2009.
19. Feng X, Xiao J, Longville B, Tan AXJ, Wu XN, Cooper MN et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 2009; 116(10): 1908-1912.e1.
20. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley Jr MA. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93(5): 610-613.
21. Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 2009; 23: 2163-2168.
22. Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisationF'beyond the TAP study'. Eye 2004; 18: 809-813.
23. Murjaneh M, García-Fiñana M, Mahmood S, Lenfestey PM, Taylor SA, Pearce IA et al. Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular agerelated macular degeneration. Br J Ophthalmol 2009; 93(4): 468-473.
24. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27): 2805-2816.
25. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al, the PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008; 145: 239-248.
26. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.
27. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147(5): 831-837.
28. Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye 2009; 23: 1633-1640.
29. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148: 409-413.
30. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2009; [Epub ahead of print 6 August 2009].